| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -520,121 | -307,291 |
| Depreciation and amortization | 8,899 | 5,835 |
| Stock-based compensation expense | 102,848 | 67,542 |
| Amortization of operating lease right-of-use assets | 6,161 | 4,028 |
| Net accretion of discounts on investments | 11,670 | 9,406 |
| Unrealized foreign exchange gain | 33,113 | 32,324 |
| Prepaid expenses and other current assets | 7,251 | 8,166 |
| Operating lease right-of-use assets | 17,575 | 17,575 |
| Other assets | 28,347 | 17,031 |
| Operating lease liabilities | 13,234 | 14,635 |
| Accounts payable | -1,761 | -19,638 |
| Accrued compensation | -3,924 | -9,872 |
| Accrued contract manufacturing expenses | 63,204 | 43,217 |
| Accrued expenses | -1,329 | -1,394 |
| Net cash used in operating activities | -430,745 | -287,440 |
| Purchases of property and equipment | 11,059 | 7,235 |
| Purchases of manufacturing facility build-out and equipment construction-in-progress | 37,493 | 29,271 |
| Purchases of investments | 918,850 | 663,535 |
| Maturities of investments | 1,183,164 | 832,964 |
| Sales of investments | 106,467 | 68,136 |
| Net cash provided by (used in) investing activities | 322,229 | 201,059 |
| Proceeds from issuance of shares through employee equity incentive plans | 9,590 | 9,284 |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock from follow-on offerings, net of issuance costs | 0 | 0 |
| Taxes paid related to the net share settlement of equity awards | 9,984 | 6,007 |
| Net cash provided by (used in) financing activities | -394 | 3,277 |
| Effect of exchange rate changes on cash and cash equivalents | 2,263 | 1,972 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -106,647 | -81,132 |
| Cash and cash equivalents at beginning of period | 389,195 | - |
| Cash and cash equivalents at end of period | 282,548 | - |
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)